Trial Overview
NCT ID: NCT07104916 Phase: PHASE2 Enrollment Target: 30 Status: Recruiting
The goal of this study is to learn how psilocybin delivered with mindfulness-based therapy may help symptoms of posttraumatic stress disorder (PTSD). This is an assessor-blinded, randomized, controlled study in participants with PTSD. The study will investigate the changes in brain activity, connectivity, and microstructural neuroplasticity assessed using EEG/EMG and multimodal MRI measures after administration of one oral dose of psilocybin, accompanied either with standard "psychological support" only; or with standard support plus Mindfulness-based Cognitive Therapy (MBCT).
Why This Matters
[Draft — editorial context needed]
Source
Event Website
ClinicalTrials.gov
